Pathogenesis of Venous Thromboembolism: When the Cup Runneth Over

ABSTRACT

A comprehensive understanding of the pathogenesis of venous thrombosis is essential for identifying patients at increased risk and who may therefore benefit from more aggressive preventive and therapeutic measures. As for other pathologies, the pathogenesis of venous thromboembolism is multifactorial. All risk factors, either congenital or acquired, are relatively “innocent” when considered alone. However, when an individual is unlucky enough to inherit one or more abnormality, compounded in many cases by environmental hazards, that person may be propelled over a threshold that precipitates the development of thrombosis. An appropriate analogy is that where “the last drop makes the cup run over.” A reinterpretation of the traditional Virchow's triad (abnormal vessel wall, abnormal blood flow, and abnormal blood constituents) was provided by Eberhard Mammen throughout his research, and this has contributed greatly to the understanding of the pathogenesis of this serious disorder. Mammen postulated immobility as the leading event, because it reduced blood flow as a result of decreased muscle contraction. The subsequent “stasis of flow” led to accumulation of blood within the intramuscular sinuses, especially of the calf, triggering hypercoagulability due to local accumulation of activated clotting factors and coagulation activation products and the simultaneous consumption of blood coagulation inhibitors. On Mammen's “hit list” nearly 20 years ago were included (among inherited abnormalities) decreased protein C, protein S, antithrombin III, plasminogen, and tissue plasminogen activator, and increased plasminogen activator inhibitor-1, whereas (among acquired predisposing conditions) surgery, trauma, previous thromboembolism, prolonged immobility and paralysis, malignancy, congestive heart failure, obesity, advanced age, pregnancy and puerperium, varicose veins, and oral contraceptives were also identified. Some two decades later, the situation has perhaps not changed so much, although studies continue to expand our knowledge of this topic, clarifying the relative contribution of each single risk factor in the pathogenesis of venous thrombosis.

KEYWORDS

Pathogenesis - thrombosis - venous thrombosis - pulmonary embolism - risk factor

REFERENCES

• 1 van Rossum A B, van Houwelingen H C, Kieft G J, Pattynama P M. Prevalence of deep vein thrombosis in suspected and proven pulmonary embolism: a meta-analysis.  Br J Radiol. 1998;  71 1260-1265
• 2 Girard P, Musset D, Parent F, Maitre S, Phlippoteau C, Simonneau G. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism.  Chest. 1999;  116 903-908
• 3 Girard P, Sanchez O, Leroyer C et al.. Evaulation du Scanner Spiralé dans l'Embolie Pulmonaire Study Group. Deep venous thrombosis in patients with acute pulmonary embolism: prevalence, risk factors, and clinical significance.  Chest. 2005;  128 1593-1600
• 4 Cushman M. Epidemiology and risk factors for venous thrombosis.  Semin Hematol. 2007;  44 62-69
• 5 Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism.  Semin Thromb Hemost. 2006;  32 651-658
• 6 Virchow R. Phlogose und Thrombose im Gefäßsystem; Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt, Germany; Staatsdruckerei 1856
• 7 Mammen E F. Pathogenesis of venous thrombosis.  Chest. 1992;  102(6, Suppl) 640S-644S
• 8 Spencer F, Becker R C. Diagnosis and management of inherited and acquired thrombophilias.  J Thromb Thrombolysis. 1999;  7 91-104
• 9 Mammen E F. Antithrombin: its physiological importance and role in DIC.  Semin Thromb Hemost. 1998;  24 19-25
• 10 Mammen E F. Clinical relevance of antithrombin deficiencies.  Semin Hematol. 1995;  32(4, Suppl 2) 2-6
• 11 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis.  N Engl J Med. 2001;  344 1222-1231
• 12 Buchanan G S, Rodgers G M, Branch D W. The inherited thrombophilias: genetics, epidemiology, and laboratory evaluation.  Best Pract Res Clin Obstet Gynaecol. 2003;  17 397-411
• 13 Crowther M A, Kelton J G. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposal classification system.  Ann Intern Med. 2003;  138 128-134
• 14 Mammen E F, Thomas W R, Seegers W H. Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (platelet cofactor II or autoprothrombin II-A).  Thromb Diath Haemorrh. 1960;  5 218-249
• 15 Simioni P. The molecular genetics of familial venous thrombosis.  Baillieres Best Pract Res Clin Haematol. 1999;  12 479-503
• 16 Griffin J H, Evatt B, Zimmerman T S et al.. Deficiency of protein C in congenital thrombotic disease.  J Clin Invest. 1981;  68 1370-1373
• 17 De Stefano V, Finazzi G, Mannucci P M. Inherited thrombophilia: pathogenesis, clinical syndromes and management.  Blood. 1996;  87 3531-3544
• 18 Franco R F, Reitsma P H. Genetic risk factors of venous thrombosis.  Hum Genet. 2001;  109 369-384
• 19 Borgel D, Gandrille S, Aiach M. Protein S deficiency.  Thromb Haemost. 1997;  78 351-356
• 20 Comp P C, Esmon C T. Recurrent venous thromboembolism in patients with a partial deficiency of protein S.  N Engl J Med. 1984;  311 1525-1528
• 21 Gandrille S, Borgel D, Ireland H et al.. Protein S deficiency: a database of mutations. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.  Thromb Haemost. 1997;  77 1201-1214
• 22 Dahlback B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.  Proc Natl Acad Sci U S A. 1994;  91 1396-1400
• 23 Bertina R M, Koeleman B P, Koster T et al.. Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature. 1994;  369 64-67
• 24 Williamson D, Brown K, Luddington R, Baglin C, Baglin T, Factor V. Cambridge: a new mutation (Arg306!Thr) associated with resistance to activated protein C.  Blood. 1998;  91 1140-1144
• 25 Bernardi F, Faioni E M, Castoldi E et al.. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype.  Blood. 1997;  90 1552-1557
• 26 Chan W P, Lee C K, Kwong Y L, Lam C K, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese.  Blood. 1998;  91 1135-1139
• 27 Rees D C, Cox M, Clegg J B. World distribution of factor V Leiden.  Lancet. 1995;  346 1133-1134
• 28 Rosendaal F R, Koster T, Vandenbroucke J P, Reitsma P H. High risk of thrombosis in patients homozygous for factor V Leiden.  Blood. 1995;  85 1504-1508
• 29 Cushman M, Tsai A W, White R H et al.. Deep vein thrombosis and pulmonary embolism in two cohorts: The Longitudinal Investigation of Thromboembolism Etiology.  Am J Med. 2004;  117 19-25
• 30 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood. 1996;  88 3698-3703
• 31 Rosendaal F R, Doggen C J, Zivelin A et al.. Geographic distribution of the 20210 G to A prothrombin variant.  Thromb Haemost. 1998;  79 706-708
• 32 Margaglione M, Brancaccio V, De Lucia D et al.. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism.  Chest. 2000;  118 1405-1411
• 33 Mammen E F. Sticky platelet syndrome.  Semin Thromb Hemost. 1999;  25 361-365
• 34 Frenkel E P, Mammen E F. Sticky platelet syndrome and thrombocythemia.  Hematol Oncol Clin North Am. 2003;  17 63-83
• 35 Weber M, Gerdsen F, Gutensohn K, Schoder V, Eifrig B, Hossfeld D K. Enhanced platelet aggregation with TRAP-6 and collagen in platelet aggregometry in patients with venous thromboembolism.  Thromb Res. 2002;  107 325-328
• 36 Clagett G P, Reisch J S. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis.  Ann Surg. 1988;  208 227-240
• 37 Rosendaal F R. Venous thrombosis: the role of genes, environment, and behavior.  Hematology (Am Soc Hematol Educ Program). 2005;  1-12
• 38 Bergqvist D. Venous thromboembolism: a review of risk and prevention in colorectal surgery patients.  Dis Colon Rectum. 2006;  49 1620-1628
• 39 Most D, Kozlow J, Heller J, Shermak M. Thromboembolism in plastic surgery.  Plast Reconstr Surg. 2005;  115 20e-30e
• 40 Rohrich R J, Rios J L. Venous thromboembolism in cosmetic plastic surgery.  Plast Reconstr Surg. 2003;  112 871-872
• 41 Hughes C E. Reduction of lipoplasty risks and mortality.  Aesth Surg. 2001;  21 161-163
• 42 Bannink L, Doggen C JM, Nelissen R GHH, Rosendaal F R. Increased risk of venous thrombosis after orthopedic and general surgery: results of the MEGA study [abstract].  J Thromb Haemost. 2005;  3(Suppl 1) 1653
• 43 White R H, Zhou H, Romano P S. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures.  Thromb Haemost. 2003;  90 446-455
• 44 Pineo G F, Hull R D. Prophylaxis of venous thromboembolism following orthopaedic surgery: mechanical and pharmacological approaches and the need for extended prophylaxis.  Thromb Haemost. 1999;  82 918-924
• 45 Ilahi O A, Reddy J, Ahmad I. Deep venous thrombosis after knee arthroscopy: a meta-analysis.  Arthroscopy. 2005;  21 727-730
• 46 van Stralen K J, Rosendaal F R, Doggen C J. Minor injuries as a risk factor for venous thrombosis.  Arch Intern Med. 2008;  168 21-26
• 47 Piccioli A, Falanga A, Baccaglini U, Marchetti M, Prandoni P. Cancer and venous thromboembolism.  Semin Thromb Hemost. 2006;  32 694-699
• 48 Franchini M, Montagnana M, Targher G, Manzato F, Lippi G. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer.  J Thromb Thrombolysis. 2007;  24 29-38
• 49 Trousseau A. Phlegmasia alba dolens. In: Clinique Médicale de l'Hôtel-Dieu de Paris. Paris; Ballière 1865: 654-712
• 50 Bergqvist D. Venous thromboembolism in cancer patients: expanding horizons.  Semin Thromb Hemost. 2002;  28(Suppl 3) 19-23
• 51 Agnelli G. Venous thromboembolism and cancer: a two way clinical association.  Thromb Haemost. 1997;  78 117-120
• 52 Sorensen H T, Mellemkjaer L, Olsen J H, Baron J A. Prognosis of cancers associated with venous thromboembolism.  N Engl J Med. 2000;  343 1846-1850
• 53 Heit J A. Cancer and venous thromboembolism: scope of the problem.  Cancer Control. 2005;  12(Suppl 1) 5-10
• 54 Hutten B A, Prins M H, Gent M, Ginsberg J, Tijssen J G, Buller H R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.  J Clin Oncol. 2000;  18 3078-3083
• 55 Prandoni P, Lensing A WA, Piccioli A et al.. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.  Blood. 2002;  100 3484-3488
• 56 Blom J W, Doggen C JM, Osanto S, Rosendaal F R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis.  JAMA. 2005;  293 715-722
• 57 Heit J A, Silverstein M D, Mohr D N, Petterson T M, O'Fallon W M, Melton III L J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.  Arch Intern Med. 2000;  160 809-815
• 58 Silverstein M D, Heit J A, Mohr D N, Petterson T M, O'Fallon W M, Melton III L J. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.  Arch Intern Med. 1998;  158 585-593
• 59 Sutherland D E, Weitz I C, Liebman H A. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment.  Am J Hematol. 2003;  72 43-52
• 60 Levitan N, Dowlati A, Remick S C et al.. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.  Medicine (Baltimore). 1999;  78 285-291
• 61 Thodiyil P A, Kakkar A K. Variation in relative risk of venous thromboembolism in different cancers.  Thromb Haemost. 2002;  87 1076-1077
• 62 Lee A Y, Levine M N. The thrombophilic state induced by therapeutic agents in the cancer patient.  Semin Thromb Hemost. 1999;  25 137-145
• 63 Bick R L. Cancer-associated thrombosis.  N Engl J Med. 2003;  349 109-110
• 64 Fisher B, Costantino J, Redmond C et al.. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.  N Engl J Med. 1989;  320 479-484
• 65 Pritchard K I, Paterson A H, Paul N A et al.. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.  J Clin Oncol. 1996;  14 2731-2737
• 66 Freytes C O. Thromboembolic complications related to central venous access catheters in cancer patients.  Semin Thromb Hemost. 2007;  33 389-396
• 67 Piazza G, Seddighzadeh A, Goldhaber S Z. Double trouble for 2,609 hospitalized medical patients who developed deep vein thrombosis: prophylaxis omitted more often and pulmonary embolism more frequent.  Chest. 2007;  132 554-561
• 68 Cohen A T, Tapson V F, Bergmann J F et al.. ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study.  Lancet. 2008;  371 387-394
• 69 Le Jeune S, Pistorius M A, Planchon B, Pottier P. Risk of venous thromboembolism in acute medical illnesses. Part 2: situations at risk in ambulatory, hospital and internal medicine settings.  Rev Med Interne. 2008;  29 462-475
• 70 Gallus A S. Travel, venous thromboembolism, and thrombophilia.  Semin Thromb Hemost. 2005;  31 90-96
• 71 Ettema H B, Kollen B J, Verheyen C C, Büller H R. Prevention of venous thromboembolism in patients with immobilization of the lower extremities: a meta-analysis of randomized controlled trials.  J Thromb Haemost. 2008;  6 1093-1098
• 72 Simpson K. Shelter deaths from pulmonary embolism.  Lancet. 1940;  ii 744
• 73 Homans J. Thrombosis of the deep leg veins due to prolonged sitting.  N Engl J Med. 1954;  250 148-149
• 74 Cruickshank J M, Gorlin R. Air travel and thrombotic episodes: the economy class syndrome.  Lancet. 1988;  2 497-498
• 75 Kuipers S, Schreijer A J, Cannegieter S C, Büller H R, Rosendaal F R, Middeldorp S. Travel and venous thrombosis: a systematic review.  J Intern Med. 2007;  262 615-634
• 76 Ten Wolde M, Kraaijenhagen R A, Schiereck J et al.. Travel and the risk of symptomatic venous thromboembolism.  Thromb Haemost. 2003;  89 499-505
• 77 United Nations Population Division .World Contraceptive Use 2001. New York, NY; United Nations 2002
• 78 Watson H G. Sex hormones and thrombosis.  Semin Hematol. 2007;  44 98-105
• 79 Royal College of Obstetricians and Gynaecologists (RCOG) .Venous Thromboembolism and Hormonal Contraception. Guideline no. 40. London, United Kingdom; Royal College of Obstetricians and Gynaecologists 2004
• 80 Gomes M P, Deitcher S R. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review.  Arch Intern Med. 2004;  164 1965-1976
• 81 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception . Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study.  Lancet. 1995;  346 1575-1582
• 82 Jick H, Jick S S, Gurewich V, Myers M W, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.  Lancet. 1995;  346 1589-1593
• 83 Bloemenkamp K W, Rosendaal F R, Helmerhorst F M, Buller H R, Vandenbroucke J P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.  Lancet. 1995;  346 1593-1596
• 84 Spitzer W O, Lewis M A, Heinemann L A, Thorogood M, MacRae K D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study.  BMJ. 1996;  312 83-88
• 85 Farley T M, Meirik O, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks.  Hum Reprod Update. 1999;  5 721-735
• 86 Kemmeren J M, Algra A, Grobbee D E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.  BMJ. 2001;  323 131-134
• 87 Mammen E F. Oral contraceptive pills and hormonal replacement therapy and thromboembolic disease.  Hematol Oncol Clin North Am. 2000;  14 1045-1059
• 88 Simioni P, Sanson B J, Prandoni P et al.. Incidence of venous thromboembolism in families with inherited thrombophilia.  Thromb Haemost. 1999;  81 198-202
• 89 Lippi G, Manzato F, Brocco G, Franchini M, Guidi G. Prothrombotic effects and clinical implications of third-generation oral contraceptives use.  Blood Coagul Fibrinolysis. 2002;  13 69-72
• 90 Tan J Y. Thrombophilia in pregnancy.  Ann Acad Med Singapore. 2002;  31 328-334
• 91 McColl M D, Ramsay J E, Tait R C et al.. Risk factors for pregnancy associated venous thromboembolism.  Thromb Haemost. 1997;  78 1183-1188
• 92 Bates S M, Greer I A, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133 844S-886S
• 93 Pomp E R, Lenselink A M, Rosendaal F R, Doggen C J. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study.  J Thromb Haemost. 2008;  6 632-637
• 94 Ros H S, Lichtenstein P, Bellocco R et al.. Pulmonary embolism and stroke in relation to pregnancy: how can high-risk women be identified?.  Am J Obstet Gynecol. 2002;  186 198-203
• 95 Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci P M. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium.  Thromb Haemost. 2002;  87 791-795
• 96 Gerhardt A, Scharf R E, Beckmann M W et al.. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.  N Engl J Med. 2000;  342 374-380
• 97 Gerhardt A, Scharf R E, Zotz R B. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium.  Thromb Haemost. 2003;  90 77-85
• 98 Gammaro L, Lippi G, Bottini E et al.. Severe preeclampsia in antithrombin III deficiency with no history of venous thromboembolism.  J Nephrol. 2001;  14 312-315
• 99 Brenner B. Thrombophilia and fetal loss.  Semin Thromb Hemost. 2003;  29 165-170
• 100 Rodger M A, Paidas M. Do thrombophilias cause placenta-mediated pregnancy complications?.  Semin Thromb Hemost. 2007;  33 597-603
• 101 Gerbasi F R, Bottoms S, Farag A, Mammen E F. Changes in hemostasis activity during delivery and the immediate postpartum period.  Am J Obstet Gynecol. 1990;  162 1158-1163
• 102 Hickey M, Davis S R, Sturdee D W. Treatment of menopausal symptoms: what shall we do now?.  Lancet. 2005;  366 409-421
• 103 Nippita T A, Baber R J. Premature ovarian failure: a review.  Climacteric. 2007;  10 11-22
• 104 Sare G M, Gray L J, Bath P M. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis.  Eur Heart J. 2008;  29 2031-2041
• 105 Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis.  Thromb Haemost. 2008;  99 338-342
• 106 Canonico M, Plu-Bureau G, Lowe G D, Scarabin P Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.  BMJ. 2008;  336 1227-1231
• 107 Samama M M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study.  Arch Intern Med. 2000;  160 3415-3420
• 108 White H R, Gettner S, Newman J, Trauner K B, Romano S P. Predictors of rehospitalization for symptomatic venous thromboembolismafter total hip arthroplasty.  N Engl J Med. 2000;  343 1758-1764
• 109 Abdollahi M, Cushman M, Rosendaal F R. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use.  Thromb Haemost. 2003;  89 493-498
• 110 Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen P W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis.  Circulation. 2008;  117 93-102
• 111 Bick R L, Baker W F. Antiphospholipid syndrome and thrombosis.  Semin Thromb Hemost. 1999;  25 333-350
• 112 Wahl D G, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis.  Lupus. 1998;  7 15-22
• 113 Galli M, Barbui T. Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests.  Semin Thromb Hemost. 2005;  31 17-24
• 114 Sofi F, Marcucci R, Abbate R, Gensini G F, Prisco D. Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis.  Am J Med. 2007;  120 728-733
• 115 den Heijer M, Rosendaal F R, Blom H J, Gerrits W B, Bos G M. Hyperhomocysteinemia and venous thrombosis: a meta-analysis.  Thromb Haemost. 1998;  80 874-877
• 116 Cattaneo M. Hyperhomocysteinemia and venous thromboembolism.  Semin Thromb Hemost. 2006;  32 716-723
• 117 Simioni P, Sanson B J, Prandoni P et al.. Incidence of venous thromboembolism in families with inherited thrombophilia.  Thromb Haemost. 1999;  81 198-202